Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | LPL | P06858 | 12/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 12/20 | 0.41 |
| ▸ | F11 | P03951 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA3 | P07451 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.36 |
| ▸ | SNCA | P37840 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12099849 | 0.92 | CA1 (0.51) | CA1CA2CA9LPLLIPG | |
| SCHEMBL16622963 | 0.86 | CA1 (0.49) | CA1CA2CA9LPLLIPG | |
| SCHEMBL1129399 | 0.86 | CA1 (0.49) | CA1CA2CA9LPLLIPG | |
| SCHEMBL23575375 | 0.85 | CA1 (0.48) | CA1CA2CA9LPLLIPG | |
| SCHEMBL1129134 | 0.85 | CA1 (0.48) | CA1CA2CA9LPLLIPG | |
| SCHEMBL14230903 | 0.84 | CA1 (0.47) | CA1CA2CA9LPLLIPG | |
| SCHEMBL16291830 | 0.83 | CA1 (0.42) | CA1CA2CA9LPLLIPG | |
| SCHEMBL16291832 | 0.83 | CA1 (0.42) | CA1CA2CA9LPLLIPG | |
| SCHEMBL16291829 | 0.83 | CA1 (0.42) | CA1CA2CA9LPLLIPG | |
| SCHEMBL16308661 | 0.83 | CA1 (0.42) | CA1CA2CA9LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113549010-B | Preparation and application of compound with AMPK (AMPK) agonistic activity and prodrug thereof | 中国科学院上海药物研究所 | 2023-10-20 | — | — | CN | disclosed |
| CN-113549010-A | Preparation and application of compound with AMPK agonistic activity and prodrug thereof | 中国科学院上海药物研究所 | 2021-10-26 | — | — | CN | disclosed |
| US-9180123-B2 | N-link hydroxamic acid derivatives useful as antibacterial agents | PFIZER INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150182513-A1 | N-Link Hydroxamic Acid Derivatives Useful As Antibacterial Agents | PFIZER INC. (US) | 2015-07-02 | — | — | US | disclosed |
| US-9018384-B2 | N-link hydroxamic acid derivatives useful as antibacterial agents | PFIZER INC. (US) | 2015-04-28 | — | — | US | disclosed |
| US-20140343031-A1 | N-Link Hydroxamic Acid Derivatives Useful As Antibacterial Agents | PFIZER INC. (US) | 2014-11-20 | — | — | US | disclosed |
| EP-2512474-B1 | N-LINKED HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | PFIZER (US) | 2014-11-05 | — | — | EP | disclosed |
| US-8846933-B2 | N-link hydroxamic acid derivatives useful as antibacterial agents | PFIZER INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140128363-A1 | N-Link Hydroxamic Acid Derivatives Useful As Antibacterial Agents | PFIZER (US) | 2014-05-08 | — | — | US | disclosed |
| US-8664401-B2 | N-linked hydroxamic acid derivatives useful as antibacterial agents | PFIZER INC. (US) | 2014-03-04 | — | — | US | disclosed |
| EP-2512474-A1 | N-LINKED HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | Pfizer Inc. (US) | 2012-10-24 | — | — | EP | disclosed |
| US-20120258948-A1 | N-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents | PFIZER INC. | 2012-10-11 | — | — | US | disclosed |
| WO-2011073845-A1 | N-LINKED HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | PFIZER INC. (US) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150182513-A1 | N-Link Hydroxamic Acid Derivatives Useful As Antibacterial Agents | LPXN, NAAA, AGXT | CA1 3462/4885CA2 1948/4885CA9 1106/4885 |
| US-20120258948-A1 | N-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents | LPXN, LCT, HAX1 | CA1 2504/4885CA2 2300/4885CA9 966/4885 |
| US-20140128363-A1 | N-Link Hydroxamic Acid Derivatives Useful As Antibacterial Agents | LPXN, NAAA, AGXT | CA1 3462/4885CA2 1948/4885CA9 1106/4885 |
| US-20140343031-A1 | N-Link Hydroxamic Acid Derivatives Useful As Antibacterial Agents | LPXN, NAAA, AGXT | CA1 3462/4885CA2 1948/4885CA9 1106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.